Agilis Biotherapeutics Co-Sponsors and Participates in Genetic Rx Boston Conference

Meeting Convenes Experts in Field of Genetic Medicine and Rare/Ultra-rare Disorders

Cambridge, Mass., December 3, 2015--Agilis Biotherapeutics, LLC (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), announced today that Agilis was a co-sponsor of the Genetic Rx Conference in Boston, Mass. Dr. Gregory Robinson, Chief Scientific Officer of Agilis, moderated the panel on "Rare and Ultra-Rare Genetic Disorders: Breakthroughs and Challenges", bringing together academic and industry experts to discuss the successes and challenges involved with the treatment of rare/ultra-rare disorders. The topics covered included novel technologies, clinical trial design, patient recruitment, and regulatory advances.

"This conference invites key opinion leaders from academia and industry to discuss novel genetic treatments for very rare genetic disorders for which no therapies are available," stated Dr. Robinson. "There has been an amazing advancement in the number and type of technologies in development to treat these devastating disorders. Agilis is pleased to co-sponsor this unique conference and discuss strategies that show promise, as well as challenges that the field continues to face. Agilis' progress with its gene therapy programs for the treatment of Angelman syndrome and Friedreich's ataxia provides evidence for the potential of this exciting treatment approach for rare disorders of the central nervous system."

Boston Biotech Conference's (BBC's) Genetic Rx conference brings together academic experts and industry leaders to discuss new genetic medicines as treatments for patients with rare and ultra-rare genetic diseases. The sessions deal with the key issues facing the development of these therapeutics for these underserved diseases. BBC focuses on building a vibrant community of biopharma leaders to help to drive innovation through discussions, information-sharing, networking, and corporate development within the biopharma community.

About Agilis Biotherapeutics, LLC

Agilis is advancing innovative DNA therapeutics designed to provide long-term efficacy for patients with debilitating, often fatal, rare genetic diseases that affect the central nervous system. Our therapies are engineered to impart sustainable clinical benefits, and potentially a functional cure, by inducing persistent expression of a therapeutic gene. The Company's technology is aimed at the precise targeting and restoration of lost gene function, while avoiding unintended off-target effects. Our integrated strategy increases the efficiency of developing DNA therapeutics into safe, targeted gene therapies that achieve long-term efficacy and enable patients to remain asymptomatic without continuous invasive treatment. Agilis' rare disease programs are focused on gene therapy for Friedreich's ataxia, Angelman syndrome and Fragile X syndrome, rare genetic diseases that include severe neurological deficits and result in physically debilitating conditions. Friedreich's ataxia is the most common hereditary ataxia with an estimated 5,000 to 10,000 patients in the U.S. There are an estimated 10,000 to 15,000 people living with Angelman syndrome in the US. Fragile X syndrome is the most common known cause of inherited intellectual disability with an estimated 64,000 patients living in the U.S.

We invite you to visit our website at www.agilisbio.com

Safe Harbor Statement

Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

###

For more information, contact:

Agilis Biotherapeutics

Dr. Jodi Cook

Vice President, Operations

Email: jcook@agilisbio.com

Phone: 510-673-7809